Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig 3 — Pooled estimates of the network meta-analysis. (A) Pooled hazard ratios (95% credible intervals) for progression free survival (upper triangle) and overall survival (lower triangle). (B) Pooled odds ratios (95% credible intervals) for adverse events of grade 3 or higher (upper triangle) and objective response rate (lower triangle). Data in each cell are hazard or odds ratios (95% credible intervals) for the comparison of row-defining treatment versus column-defining treatment. Hazard ratios less than 1 and odds ratios more than 1 favour row-defining treatment. Significant results are in bold. Osi=osimertinib; Dac=dacomitinib; Afa=afatinib; Erl=erlotinib; Gef=gefitinib; Ico=icotinib; Cet=cetuximab; Bev=bevacizumab; Gef+P=gefitinib plus pemetrexed; PbCT=pemetrexed based chemotherapy; PfCT=pemetrexed free chemotherapy